Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ironwood Pharmaceuticals (IRWD) over the last 12 years, with Q3 2025 value amounting to $2.2 million.

  • Ironwood Pharmaceuticals' Other Operating Expenses rose 1365000.0% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 15281.91%. This contributed to the annual value of $2.6 million for FY2024, which is 9976.72% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Other Operating Expenses is $2.2 million, which was up 1365000.0% from -$250000.0 recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Other Operating Expenses' 5-year high stood at $1.1 billion during Q2 2023, with a 5-year trough of -$250000.0 in Q2 2025.
  • Its 3-year average for Other Operating Expenses is $116.5 million, with a median of $2.1 million in 2024.
  • The largest annual percentage gain for Ironwood Pharmaceuticals' Other Operating Expenses in the last 5 years was 1365000.0% (2025), contrasted with its biggest fall of 11209.48% (2025).
  • Quarter analysis of 3 years shows Ironwood Pharmaceuticals' Other Operating Expenses stood at $5.6 million in 2023, then tumbled by 98.7% to $73000.0 in 2024, then skyrocketed by 2913.7% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, -$250000.0 for Q2 2025, and $18.6 million during Q1 2025.